You are using an outdated browser. Please upgrade your browser to improve your experience.

olmutinib

Ligand Summary
Ligand Structure
Rendered image for the query structure
Description
Olmutinib is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) for the treatment of non-small cell lung cancer (NSCLC). Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymatic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.
Synonyms & Links
DrugCentral: 5210
LyCHI:  HN5ARD4YQZDD


Target Activities